The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership

• In August and September 2026, Natera, Inc. reported new real-world data in Blood Neoplasia supporting the prognostic and predictive value of its Signatera MRD test in lymphoma, while also announcing a national partnership with Susan G. Komen and a Signatera-based response-monitoring collaboration in Angiex’s AGX101 Phase I trial.
• Together, these developments strengthen Signatera’s clinical evidence base, extend its visibility in breast cancer advocacy, and embed the assay more deeply into emerging oncology treatment and monitoring frameworks.
• We’ll now explore how this expanded real-world validation of Signatera in lymphoma may influence Natera’s broader investment narrative and outlook.

Find 47 companies with promising cash flow potential yet trading below their fair value.

Natera Investment Narrative Recap

To own Natera, you need to believe Signatera can become a standard molecular residual disease tool across multiple cancers while the company manages high spending and ongoing losses. The new lymphoma data deepens clinical validation in hematologic malignancies, which may support guideline and reimbursement momentum, but it does not by itself remove the near term risk that reimbursement decisions or cost pressures could slow progress toward profitability.

Among the recent announcements, the publication of real world lymphoma data in Blood Neoplasia is most directly relevant. It shows Signatera offering stronger prognostic and predictive performance than PET/CT in a broad, heterogeneous patient group, including after CAR T therapy. For investors, this reinforces the core catalyst that more robust, peer reviewed evidence in additional cancers could be important for future coverage decisions and test adoption in oncology.

Yet while these clinical wins are encouraging, investors should still pay close attention to how Natera balances heavy R&D and AI investment with its path to profitability and reimbursement clarity...

Read the full narrative on Natera (it's free!)

Natera's narrative projects $4.2 billion revenue and $300.7 million earnings by 2029.

Uncover how Natera's forecasts yield a $282.14 fair value, a 14% downside to its current price.

Exploring Other Perspectives

Against this backdrop, the most optimistic analysts were already projecting around US$5.3 billion in 2029 revenue and US$887.8 million in earnings, which assumes far faster progress on reimbursement and profitability than the baseline view; depending on how you interpret the new lymphoma data and ongoing regulatory uncertainty, you may see those forecasts as either exciting or overly aggressive, so it is worth comparing several viewpoints before deciding what you believe.

Explore 5 other fair value estimates on Natera - why the stock might be worth 15% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Natera research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com